Details for Patent: 8,746,242

✉ Email this page to a colleague

Patent 8,746,242 protects INCRUSE ELLIPTA, ANORO ELLIPTA, ARNUITY ELLIPTA, BREO ELLIPTA, and TRELEGY ELLIPTA, and is included in five NDAs.

Protection for ANORO ELLIPTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-seven patent family members in twenty countries.

Title:	Medicament dispenser
Abstract:	A medicament dispenser for use with at least one medicament carrier carrying multiple distinct medicament portions, said medicament dispenser comprising (a) a dispensing mechanism actuable for dispensing the distinct medicament portions carried by the at least one medicament carrier; (b) a mouthpiece; and (c) a cover for the mouthpiece, the cover being movably mounted to the dispenser for sequential movement from a first position, in which the mouthpiece is covered, to a second position, in which the mouthpiece is at least part-uncovered, to a third position in which the mouthpiece is uncovered; wherein the cover is adapted to couple with the dispensing mechanism such that movement of the cover from the second position to the third position, but not the first position to the second position, results in actuation of the dispensing mechanism.
Inventor(s):	Connell; Hugh Alexander (Evesham, GB), Harvey; Stephen James (Ware, GB), Tansley; Robert William (Bidford on Avon, GB)
Assignee:	Glaxo Group Limited (Brentford, Middlesex, GB)
Application Number:	11/996,762
Patent Claim Types: see list of patent claims	Composition; Device; Use;

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Glaxo Grp England	INCRUSE ELLIPTA	umeclidinium bromide	POWDER;INHALATION	205382-001	Apr 30, 2014		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Glaxosmithkline	ANORO ELLIPTA	umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	203975-001	Dec 18, 2013		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up			Y		⤷ Sign Up
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-003	May 17, 2018		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up			Y		⤷ Sign Up
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-001	Aug 20, 2014		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up			Y		⤷ Sign Up
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-002	Aug 20, 2014		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up			Y		⤷ Sign Up
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-003	May 12, 2023		RX	Yes	No	⤷ Sign Up	⤷ Sign Up			Y		⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0515584.1	Jul 28, 2005

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006273856	⤷ Sign Up
Brazil	PI0614568	⤷ Sign Up
Canada	2616193	⤷ Sign Up
China	101272818	⤷ Sign Up
Cyprus	1122241	⤷ Sign Up
Denmark	1907037	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration